<DOC>
	<DOCNO>NCT02904902</DOCNO>
	<brief_summary>This study investigate efficacy , safety pharmacokinetics adalimumab Japanese subject moderate severe Hidradenitis Suppurativa ( HS ) .</brief_summary>
	<brief_title>Open-label Study Adalimumab Japanese Subjects With Hidradenitis Suppurativa</brief_title>
	<detailed_description>Prior initiation study , global Phase 2b study pivotal Phase III study complete Western country market authorization adalimumab approve US European Union ( EU ) treatment subject HS . The difference study global study include sample size , study design , duration , race .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant must diagnosis hidradenitis suppurativa ( HS ) ; Participant must HS symptom least 6 month prior Baseline ; HS lesion must present least 2 distinct anatomic area , one must Hurley Stage II Hurley Stage III ; Participant must stable HS least 2 month ( 60 day ) prior Screening also Baseline visit ; Participant must total AN count great equal 3 Baseline visit . Prior treatment adalimumab antitumor necrosis factor ( TNF ) therapy participation adalimumab trial ; Any active skin lesion condition may interfere assessment HS ; Participants receive antibiotic treatment HS within 28 day prior Baseline visit allow per protocol . Participant permit oral antibiotic treatment ( doxycycline minocycline ) HS stable dose least 28 day prior Baseline visit ; Participants receive prescription topical therapy treatment HS within 14 day prior Baseline visit ; Participants receive systemic nonbiologic therapy potential therapeutic impact HS le 28 day prior Baseline visit ; Participants receive oral concomitant analgesic ( nonopioids opioids ) HSrelated pain within 14 day prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adalimumab</keyword>
	<keyword>japanese participant</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>